New FDA Indication for Zofran Tablets

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 11
Volume 8
Issue 11

RESEARCH TRIANGLE PARK, NC-Zofran (ondansetron HCl), Glaxo Wellcome’s 5HT3 antagonist antiemetic, has received FDA approval for a new indication and a new tablet strength

RESEARCH TRIANGLE PARK, NC—Zofran (ondansetron HCl), Glaxo Wellcome’s 5HT3 antagonist antiemetic, has received FDA approval for a new indication and a new tablet strength

Zofran is now indicated for the prevention of nausea and vomiting associated with single-day highly emetogenic cancer chemotherapy in adults, ie, chemotherapy in which the likelihood of nausea and vomiting is greater than 90% without prior antiemetic treatment.

The Zofran dose for highly emetogenic chemotherapy is 24 mg once daily, which can be given via the newly approved 24-mg tablet or three 8-mg tablets.

Zofran is also indicated for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy in adults and children, the prevention of nausea and vomiting associated with radiotherapy in adults, and the prevention of postoperative nausea and vomiting in adults.

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content